Dorgenmeltucel-L

Drug Profile

Dorgenmeltucel-L

Alternative Names: HyperAcute Melanoma; Melanoma immunotherapy - NewLink Genetics; NLG-12036

Latest Information Update: 07 Aug 2015

Price : $50

At a glance

  • Originator NewLink Genetics Corporation
  • Class Cancer vaccines; Cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant melanoma

Most Recent Events

  • 07 Aug 2015 Dorgenmeltucel-L is still in phase II trials for Malignant melanoma in the USA
  • 01 Apr 2014 NewLink Genetics Corporation initiates a phase IIb trial for Malignant melanoma in USA (NCT02054520)
  • 25 Feb 2014 NewLink Genetics Corporation plans a phase IIb trial for Malignant melanoma in USA (NCT02054520)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top